更新于 12月24日

Clinical Portfolio Manager

面議
  • 上海浦東新區(qū)
  • 5-10年
  • 碩士
  • 全職
  • 招1人

職位描述

臨床試驗(yàn)項(xiàng)目PM
Major Responsibilities:
1.Portfolio management and support: Provide regular reports with dashboards and insights to the management team to support the portfolio-wide vision of R&D progress. Participate and support portfolio review meetings, ensuring the execution of decisions.
2.Project management: as a key member of the clinical development project management team, work closely with project leaders to develop and manage detailed project plans, timelines, and budgets. Coordinate cross-functional teams to ensure project progress, and milestones are met.
3.Continuous process improvement: Identify opportunities for process improvements during project participation and implement best practices to enhance project efficiency and effectiveness across the clinical development portfolio.
4.Resource management: Coordinate to ensure project resource needs. Establish a mechanism to collect operational performance from platforms, operate to improve shared resource allocation, to ensure project resource prioritization.
5.Perform other duties as assigned.
Qualifications:
1.Education: Master’s degree in medicine, pharmacy or bio-technology, project management or relevant fields (e.g., Biotechnology, Biomedicine, Life Sciences, etc). Advanced degree preferred.
2.Experience: Minimum of 6 years of clinical development, or project management experience in the biotechnology or pharmaceutical industry, a focus on cell and gene therapy is preferred.
3.Skills:
Organizational and coordination skills
Communicational skills
Time management skills
Problem-solving skills
Learning agility
Flexibility
Leadership skills

工作地點(diǎn)

張江高科·佑越國際

職位發(fā)布者

相美玲/招聘小姐姐

立即溝通
公司Logo南京傳奇生物科技有限公司
關(guān)于傳奇生物傳奇生物(NASDAQ: LEGN)是一家處于臨床階段的全球生物制藥公司,成立于2014年,并于美國時(shí)間2020年6月5日在納斯達(dá)克掛牌上市,成為國內(nèi)第一家CART療法上市公司。傳奇生物專注于腫瘤和其他領(lǐng)域的新型細(xì)胞療法的開發(fā)。目前在全球免疫細(xì)胞療法領(lǐng)域位列第一方陣,和合作伙伴Janssen將最領(lǐng)先的產(chǎn)品LCAR-B38M細(xì)胞制劑已推進(jìn)至在美國、歐洲藥品上市審評(píng)階段,有望解決多發(fā)性骨髓瘤治療的世界級(jí)難題。與此同時(shí),傳奇生物還有多款在研CAR-T療法,用于血液瘤、實(shí)體瘤及其它疑難疾病的治療。目前,傳奇生物在美國、中國和歐洲已擁有1000余名員工,以差異化技術(shù)、全球化研發(fā)網(wǎng)絡(luò)和專業(yè)的生產(chǎn)策略為有力支撐,為患者提供發(fā)現(xiàn)、開發(fā)和制造一流的細(xì)胞療法創(chuàng)造了可能。公司已入選江蘇省戰(zhàn)略性新興產(chǎn)業(yè)發(fā)展專項(xiàng)資金項(xiàng)目,江蘇省精準(zhǔn)細(xì)胞免疫治療工程技術(shù)研究中心,榮獲江蘇省科技進(jìn)步獎(jiǎng)、“中國生物醫(yī)藥產(chǎn)業(yè)鏈創(chuàng)新風(fēng)云榜”并獲“鯤鵬獎(jiǎng)”,入選“2020中國獨(dú)角獸”、“中國醫(yī)藥創(chuàng)新企業(yè)100強(qiáng)”。
公司主頁